Is Vismodegib good for treating basal cell carcinoma?

Vismodegib's first approval follows results from the ERIVANCE study, which showed results in treating localized or advanced metastatic basal cell carcinoma when excision alone does not lead to cure. The ERIVANCE study showed an efficacy rate of 45% in patients with locally advanced disease. Among patients with metastatic basal cell carcinoma, the independently assessed response rate was 30%. A systematic review showed that the complete response rate in patients with locally advanced basal cell carcinoma ranged from 0% to 54.1%, with a weighted average of 31.1%. Partial response rates in patients with locally advanced disease ranged from 25.5% to 66.7%, with a weighted average of 33.6%. Partial response demonstrated a reduction in total tumor size of more than 30%.